French Navy strengthens anti-submarine warfare capabilities with SonoFlash sonobuoy from Thales
18.3.2021 14:54:00 EET | Business Wire | Press release
The French Navy has selected the SonoFlash new-generation sonobuoy from Thales. Unveiled at the Euronaval show in October 2018, SonoFlash will enable France to reach its strategic capability goal for acoustic sensors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005484/en/
Artist’s impression of a SonoFlash sonobuoy at sea © Thales
The threat posed by submarines is evolving rapidly. Three decades ago, only the superpowers had a true undersea warfare capability, but numerous countries now deploy modern submarine fleets. At the same time, forces increasingly operate in littoral waters, which are much more complex for sonar systems, rather than in the relative certainty of open-ocean environments.
Responding to this evolving threat environment, Thales developed the SonoFlash buoy, a new-generation sonobuoy with an unequalled performance-to-mass ratio that builds on decades of expertise in sonars and acoustic sensors to offer an ambitious new solution.
Its innovative design and advanced technology include a number of key features to deliver unrivalled performance. Today's sonobuoys are either passive or active. By contrast, the SonoFlash buoy offers the best of both modes, combining a powerful, optimised low-frequency transmitter with a high-directivity passive receiver. With the combination of these two capabilities, and the added advantage of long endurance, the SonoFlash buoy is suitable for a wide array of deployment scenarios.
Fully compatible with the other families of Thales sonars, the SonoFlash buoy offers high tactical flexibility and opens up promising new opportunities for multistatic operation. Coupled with the FLASH dipping sonar, for example, the SonoFlash buoy enables an aircraft to expand its coverage area and respond with greater agility to evasive manoeuvres by a submarine. Thanks to its digitised signal and optimal communication range, the SonoFlash buoy data can be readily exploited by any piloted or remotely piloted aircraft, naval vessel or shore centre equipped with a sonobuoy processing system.
The French Navy will be the first operational user of the SonoFlash buoy, which will be deployed by the modernised Atlantique 2 maritime patrol aircraft and NH90 Caiman tactical transport helicopters. It will be delivered to the Navy from 2025 and could be available in export markets to equip all modern maritime patrol aircraft and helicopters as well as all types of unmanned platforms, including autonomous surface vehicles and rotary-wing (VTOL) and fixed-wing UAVs equipped with a suitable multi-sonobuoy dispenser.
Manufactured in France with a network of SMEs such as TELERAD, SelhaGroup and Realmeca, the SonoFlash buoy relies on Thales’s expertise in acoustic sensor technology to contribute to France’s desire for independence in strategic industries.
“Thales has packed 10 years of innovation in hardware and digital technologies into a tube measuring 91.4 cm long and 12.3 cm in diameter. SonoFlash extends the range of a naval force's anti-submarine warfare operations, outclassing all other sonobuoys in the market today and offering a versatile and easy-to-deploy solution for tracking submarines from any piloted or remotely piloted aircraft, frigate or unmanned surface vehicle. We are grateful to the DGA and the Navy for the trust they have placed in us and delighted to be working with French partner SMEs to bring this project to a successful conclusion and restore France's sovereign capabilities in sonobuoys.” Alexis Morel, VP Underwater Systems, Thales.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005484/en/
Contact information
Thales, Media Relations
Land and Naval Defence
Faïza Zaroual
+33 (0)7 64 25 99 31
faiza.zaroual@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
